As federal contractors and grant recipients navigate the changing landscape of diversity, equity, and inclusion (DEI) programs, the Trump administration’s rescinding of Executive Order No. 11246 (EO) raises new concerns about potential False Claims Act (FCA) liability for non-compliance.
Continue Reading Impact of Trump Administration’s Executive Order on DEI Programs and FCA LiabilityExecutive Order on DEI Programs: Implications for Healthcare and False Claims Act Risks
The Trump administration’s recent executive order targeting diversity, equity, and inclusion (DEI) programs is reshaping the landscape for healthcare providers, with potential legal and regulatory implications that are still unfolding.
Continue Reading Executive Order on DEI Programs: Implications for Healthcare and False Claims Act RisksCOVID-19 Relief Scrutiny
We recently co-authored an article for The Banking Law Journal about the Department of Justice’s (DOJ) ongoing efforts to target businesses it alleges to have fraudulently received COVID-19 relief funds.
Continue Reading COVID-19 Relief ScrutinyRegister Now: 10th Annual Nashville Healthcare Fraud Conference | December 12-13
Join us for the 10th Annual Nashville Healthcare Fraud Conference, hosted by Bass, Berry & Sims and the Tennessee Hospital Association. This highly anticipated, complimentary virtual program will take place during the mornings of December 12 and 13 and is approved for 7.75 hours of CLE credit, including ethics.
Continue Reading Register Now: 10th Annual Nashville Healthcare Fraud Conference | December 12-13Fraud and Abuse Chapter of Health Law Handbook, 2024-2025 Edition
We contributed to the Fraud and Abuse Chapter of the Health Law Handbook, 2024-2025 Edition. In the portion of our content, titled “Healthcare Fraud and Abuse Update,” we outlined regulatory developments, key court decisions and noteworthy settlements related to the Anti-Kickback Statute and Stark Law.
Continue Reading Fraud and Abuse Chapter of Health Law Handbook, 2024-2025 EditionFalse Claims Act Settlements to Know from Q3 2024
The third quarter of this year brought numerous high-dollar False Claims Act (FCA) settlements involving a variety of industries and alleged conduct.
Continue Reading False Claims Act Settlements to Know from Q3 2024Series on Healthcare Fraud Risk for The Compliance & Ethics Blog
I recently authored a two-part article series published on The Compliance & Ethics Blog highlighting key updates in healthcare fraud compliance and enforcement, including insights from the firm’s annual 2023 Healthcare Fraud & Abuse Review and updates thus far in 2024.
Continue Reading Series on Healthcare Fraud Risk for The Compliance & Ethics BlogRite Aid and OptumRx Settlements Highlight Enforcement Focus on Pharmacy Corresponding Responsibility for Dispensing Controlled Substances
On July 10, the Department of Justice (DOJ) announced a nearly $410 million settlement with Rite Aid Corporation to resolve allegations that Rite Aid and its affiliates ignored red flags and knowingly dispensed unlawful controlled substances in violation of the False Claims Act (FCA) and Controlled Substances Act (CSA).
Continue Reading Rite Aid and OptumRx Settlements Highlight Enforcement Focus on Pharmacy Corresponding Responsibility for Dispensing Controlled SubstancesFalse Claims Act Settlements to Know from Q2 2024
Halfway through 2024, the government’s False Claims Act (FCA) enforcement efforts show few signs of letting up. Last month alone, the Department of Justice (DOJ) announced at least five eight-figure FCA settlements, resolving allegations ranging from unlawful kickbacks to upcoding to improper subcontracting to cybersecurity violations.
Continue Reading False Claims Act Settlements to Know from Q2 2024Watch Now | Legal Rx: How to Navigate Controlled Substances Enforcement & Diversion Webinar
In a recent webinar, we discussed the recent increase in government enforcement against healthcare providers under the Controlled Substances Act (CSA) that has occurred over the past year.
Continue Reading Watch Now | Legal Rx: How to Navigate Controlled Substances Enforcement & Diversion Webinar